Practical recommendations for the management of adenocarcinoma of the pancreas

Drugs

Volumn 57, Issue 1, 1999, Pages 69-79

  Sporn, Jonathan R ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN; STREPTOZOCIN;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; LIVER METASTASIS; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; REVIEW;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; MITOMYCINS; PALLIATIVE CARE; PANCREATIC NEOPLASMS;

EID: 0032940541     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957010-00006     Document Type: Review

References (48)

1. 1. Evans DB, Abbruzzese JL, Rich TA. Cancer of the pancreas. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997
2. 2. Metz DC. Diagnosis and treatment of pancreatic neuroendocrine tumors. Semin Gastrointest Dis 1995; 6: 67-78
3. 3. Lillemoe KD, Pitt HA. Palliation of pancreatic carcinoma. Cancer 1996; 78: 605-14
4. 4. Lieberman MD, Kilburn H, Lindsey M, et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222: 638-45
5. 5. Thomas PRM. Radiotherapy for carcinoma of the pancreas. Semin Oncol 1996; 23: 213-9
6. 6. Smith FP, Hoth DF, Levin B, et al. 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980; 46: 2014-8
7. 7. Wiggans RG, Woolley III PV, Macdonald JS, et al. Phase II trial of streptozotocin, mitomycin-C and 5-flourouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 1978; 41: 387-91
8. 8. Kaiser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903
9. 9. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006-10
10. 10. Whittington R, Bryer MP, Haller DG, et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Rad Oncol Biol Phys 1991; 21: 1137-43
11. 11. Neoptolemos JP, Baker P, Beger H, et al. Progress report: a randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1). Int J Pancreatol 1997; 21: 97-104
12. 12. Jessup JM, Steele Jr G, Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993; 128: 559-64
13. 13. Hoffman JP, Weese JL, Solin LJ, et al. A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. Am J Surg 1995; 169: 71-8
14. 14. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 317-23
15. 15. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15: 928-37
16. 16. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996, 171: 118-25
17. 17. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads) + 5-fluorouracil, and high dose radiation + 5-fluorouracil. Cancer 1981; 48: 1705-10
18. 18. Whittington R, Neuberg D, Tester WJ, et al. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995; 13: 227-32
19. 19. Ishii H, Okada S, Tokuuye K, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997; 79: 1516-20
20. 20. Moertel CG, Gunderson LL, Mailliard JA, et al. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. J Clin Oncol 1994; 12: 21-7
21. 21. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3: 373-8
22. 22. Gastrointestinal Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751-5
23. 23. Schnall SF, Macdonald JS. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996, 23: 220-8
24. 24. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ 1980; 281: 1589-91
25. 25. Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic cancer: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65: 2207-12
26. 26. Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-5
27. 27. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13
28. 28. Whitehead RP, Jacobson J, Brown TD, et al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997; 15: 2414-9
29. 29. Scher RM, Kosierowski R, Lusch C, et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1996; 13: 347-54
30. 30. DiBartolomeo M, Bajetta E, Somma L, et al. Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology 1996; 53: 54-7
31. 31. Schwartz GK, Casper ES. A phase II trial of doxorubicin HCI liposome injection in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 1995; 13: 77-82
32. 32. Pazdur R, Merapol NJ, Casper ES, et al. Phase II trial of ZD1694 (tomudex) in patients with advanced pancreatic cancer. Invest New Drugs 1996; 13: 355-8
33. 33. Friess H. Beger HG, Kunz J, et al. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 1996; 16: 915-20
34. 34. Bolli E, Saccomanno S, Mondini G, et al. 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. Cancer Chemother Pharmacol 1995; 35: 339-42
35. 35. Scheithauer W, Kornek G, Raderer M, et al. Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage colony-slimulating factor in patients with advanced pancreatic adenocarcinoma. J Cancer, Res Clin Oncol 1995; 121 Suppl. 3: R7-10
36. 36. Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 1985; 42: 69-71
37. 37. Rigg A, Cunningham D, Gore M, et al. A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Br J Cancer 1997; 75: 101-5
38. 38. Sparano JA, Lipsitz S, Wadler S, et al. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-α in patients with advanced pancreatic cancer. Am J Clin Oncol 1996; 19: 546-51
39. 39. Colleoni M, Nelli P, Vicario G, et al. Phase II study of oral 1-leucovorin, 120-hour fluorouracil infusion and carboplatin in advanced pancreatic cancer. Tumori 1996; 82: 573-5
40. 40. Evans TR, Lofts FJ, Mansi JL, et al. A phase II sludy of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 1996; 73: 1260-4
41. 41. Sporn JR, Buzaid AC, Slater D, et al. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-α-2b, and cisplatin. Am J Clin Oncol 1997; 20: 81-3
42. 42. Fazeny B, Baur M, Prohaska M, et al. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer: results of a pilot study and review of the literature. J Cancer Res Clin Oncol 1997; 123: 45-52
43. 43. Wong A, Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas: a case-control study. Cancer 1993; 71: 2200-3
44. 44. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol 1997; 21: 1-12
45. 45. Sparano JA, Fisher RI, Weiss GR, et al. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother 1994; 16: 216-23
46. 46. Friess H, Gassmann M, Buchler MW. Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers. Int J Pancreatol 1997; 21: 43-50
47. 47. Giantonio BJ, Alpaugh RK, Schultz J, et al. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphyloccal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol 1997; 15: 1994-2007
48. 48. Alter CL. Palliative and supportive care of patients with pancreatic cancer. Semin Oncol 1996; 23: 229-40